From an unlikely beginning as an apprentice-run print shop to a leading CDMO for transdermal, oral thin film, and unit dose semisolid drug delivery, Tapemark continues to evolve impressively. With a substantial expansion coming to fruition, the company is positioned to be the premier player for these drug delivery technologies. As part of Pharma’s Almanac’s Road to 50 States campaign, Pharma’s Almanac Scientific Editor in Chief David Alvaro, Ph.D. met with Tapemark Senior Vice President and Chief Operating Officer Beau Garrett to discuss the macro trends shaping patient-centric formulation and these dosage forms and how Tapemark continues to innovate to reduce risk while increasing compliance.